Charles Schwab Investment Management Inc Neu Base Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.82 - $1.93 $24,367 - $57,351	29,716 New	29,716 $32,000
Q3 2021 Nov 16, 2021	SELL	$3.27 - $4.76 $51,404 - $74,827	-15,720 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$4.63 - $7.34 $117,777 - $186,714	-25,438 Reduced 61.81%	15,720 $76,000
Q3 2020 Nov 13, 2020	SELL	$7.25 - $9.71 $16,776 - $22,468	-2,314 Reduced 5.32%	41,158 $313,000
Q2 2020 Aug 14, 2020	BUY	$6.69 - $11.51 $290,827 - $500,362	43,472 New	43,472 $382,000

Ticker NBSE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,258,700
Description
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.